Dr Reddy's to scale-up of ops in the U.S.; GSK hopes for more from HGS collaboration;

@FiercePharma: GSK, Human Genome gear up for Benlysta launch. Report | Follow @FiercePharma 

> Dr Reddy's Laboratories is set for a significant scale-up of its operations in the U.S., including developing partnerships with other firms and a possible rebuilding of its research presence in this critical market. Article

> After waiting 18 years for its partnership with Human Genome Sciences to bear fruit, drug giant GlaxoSmithKline hopes the FDA approval of a new lupus treatment is just the first in a string of products springing from the collaboration. Story

> A long-running attempt to make it easier to produce and distribute copies of patented medicines for sale at cut-rate prices to the world's poorest countries has been approved by the House of Commons. News

> Mylan subsidiary Matrix Laboratories Limited has received final approval from the FDA under the President's Emergency Plan for AIDS Relief for its application for zidovudine tablets, 100 mg. Mylan release

> The early end of James Marshall's career, blamed by the actor and musician on Roche's Accutane acne drug, was an "unbelievable tragedy," former co- star Brian Dennehy said in court. Story

> Eli Lilly said Dr. Greg Plowman will become the vice president of oncology research and senior vice president of ImClone Systems research March 28. Report

> AstraZeneca has bought back 228,781 ordinary shares at 2972p apiece for cancellation. News

> Twelve parallel imported products from OPD Laboratories, Caseview and Delta Pharma have been recalled by UK regulators because of problems with patient information leaflets. Item

Biotech News

@FierceBiotech: FDA hands GSK, Human Genome Sciences landmark Benlysta approval. Story | Follow @FierceBiotech

@JohnCFierce: Epizyme gets $6M upfront/$200M milestone deal in new discovery pact with Eisai. Report | Follow @JohnCFierce

> Sanofi, Regeneron's aflibercept flunks PhIII trial. Report

> Rock Spring Ventures aims for $100M fund. News 

> Vertex's epilepsy drug headed for larger study. Story

> ThromboGenics prepares for future FDA approval filing. Item 

And Finally... About one in every 20 adults in the U.S. has survived cancer, including nearly one-fifth of all people over 65, according to new federal data, suggesting that many forms of the disease are treatable. Report

Suggested Articles

Sun Pharma has recalled one lot of its generic metformin after finding high levels of the probable carcinogen NDMA in tested lots.

Six months after WHO declared a pandemic, the list of drugs proven to work against the virus remains short. Now, Fujifilm has added its drug Avigan.

ICER said that Vertex's triplet CF therapy Trikafta would only be cost effective if the price were dropped from $311,000 to no more than $85,500.